Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone ResistanceManish Kohli, Scott M. Dehm, Yeung Ho et al.|Clinical Cancer Research|2017Cited by 164
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate CancerJamie M. Sperger, Joshua M. Lang, Kyle T. Helzer et al.|Clinical Cancer Research|2023Cited by 56
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancerMarina N. Sharifi, Martin Sjöström, Joshua M. Lang et al.|Molecular Oncology|2025Cited by 4
Data from Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone ResistanceManish Kohli, Scott M. Dehm, Yeung Ho et al.|Unknown|2023Cited by 0
Data from Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone ResistanceManish Kohli, Scott M. Dehm, Yingming Li et al.|Unknown|2023Cited by 0